Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.89 USD

105.89
498,510

-0.56 (-0.53%)

Updated Nov 11, 2024 12:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs

by Kinjel Shah

Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.

Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies

by Zacks Equity Research

Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.

Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer

by Zacks Equity Research

Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.

Kinjel Shah headshot

Forget Pfizer, Add These Big Drugmakers to Your Portfolio

by Kinjel Shah

Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.

Christopher Vargas headshot

J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?

by Christopher Vargas

An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.

Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo

by Zacks Equity Research

Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.

AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease

by Zacks Equity Research

AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.

Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis

by Zacks Equity Research

The FDA approves Eli Lilly's (LLY) Taltz injection for the treatment of adult patients with active ankylosing spondylitis. Shares rise.

Sweta Killa headshot

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

by Sweta Killa

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Has Novartis (NVS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVS) Outperforming Other Medical Stocks This Year?

Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study

by Zacks Equity Research

Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year.

Novo Nordisk's Fiasp Gets EC Approval for Label Expansion

by Zacks Equity Research

Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.

Teva Launches Generic Version of Mylan's EpiPen for KIds

by Zacks Equity Research

Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.

AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

by Zacks Equity Research

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL

by Zacks Equity Research

The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.

Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat

by Zacks Equity Research

Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.

Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%

by Zacks Equity Research

Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.

Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

by Zacks Equity Research

Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.

Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

by Zacks Equity Research

Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.

Here's Why Amgen Stock is Outperforming Its Industry Of Late

by Zacks Equity Research

Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

Amgen Wins Enbrel U.S. Patent Litigation Against Novartis

by Zacks Equity Research

Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen (AMGN). A district court decision prevents Novartis from launching Erelzi, its biosimilar version of Enbrel.

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2

by Zacks Equity Research

Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.

Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2019 results.

Has Novartis (NVS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVS) Outperforming Other Medical Stocks This Year?

NVS vs. NVO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NVS vs. NVO: Which Stock Is the Better Value Option?